Dyne Therapeutics, Inc. (DYN) has a negative trailing P/E of -5.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 9.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -18.78%, forward earnings yield 10.93%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.5 | 0.00 | 1.51 | 2.26 | - |
| 2017 | 50.9 | -0.49 | 2.04 | 7.65 | - |
| 2018 | -51.3 | 0.26 | -50.58 | 0.00 | - |
| 2019 | -80.2 | 2.22 | 77.34 | 0.00 | - |
| 2020 | -16.9 | -0.05 | 2.90 | 0.00 | - |
| 2021 | -4.1 | -0.03 | 1.64 | 0.00 | - |
| 2022 | -3.6 | -0.35 | 2.39 | 0.00 | - |
| 2023 | -3.4 | -0.15 | 8.70 | 0.00 | - |
| 2024 | -7.0 | 0.48 | 3.52 | 0.00 | - |
| 2025 | -5.6 | -1.90 | 2.58 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-9.61 | $1.37B | $-1.24B | -90.8% |
| 2017 | $0.47 | $506M | $76M | 15% |
| 2018 | $-0.47 | $0.00 | $-4.81M | - |
| 2019 | $-0.30 | $0.00 | $-13.54M | - |
| 2020 | $-4.08 | $0.00 | $-58.74M | - |
| 2021 | $-2.93 | $0.00 | $-149.28M | - |
| 2022 | $-3.18 | $0.00 | $-165.24M | - |
| 2023 | $-3.95 | $0.00 | $-235.94M | - |
| 2024 | $-3.37 | $0.00 | $-317.42M | - |
| 2025 | $-3.47 | $0.00 | $-446.21M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.16 | $-3.48 – $-2.88 | $995.73K | $178.94K – $3.11M | 12 |
| 2027 | $-3.09 | $-3.61 – $-1.90 | $65.1M | $8.92M – $210.26M | 10 |
| 2028 | $-2.27 | $-5.73 – $0.61 | $300.48M | $295.17M – $305.78M | 9 |
| 2029 | $-0.27 | $-1.01 – $0.02 | $852.23M | $153.16M – $2.66B | 3 |
| 2030 | $2.17 | $-0.14 – $8.13 | $1.41B | $253.94M – $4.41B | 3 |
